Which conditions qualify you for Mounjaro on the NHS?

What NICE TA1026 actually says about qualifying conditions

The NICE TA1026 recommendations set out the conditions list precisely. There are five: hypertension (high blood pressure), dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, established cardiovascular disease, and type 2 diabetes. Tirzepatide is recommended alongside a reduced-calorie diet and increased physical activity for adults who have a BMI of at least 35 and at least one of these five conditions, though the number required changes by phase, as explained below.

One thing worth clearing up: a lot of people arrive at this question assuming any weight-related health problem counts. It does not. Joint pain, fatty liver, or polycystic ovary syndrome, for instance, do not appear on the NHS qualifying list under TA1026, even though they are clinically significant. The five conditions above are the ones that matter for NHS access specifically.

The ethnic-background adjustment is applied throughout. For people of South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean heritage, NICE applies a 2.5 kg/m² lower BMI threshold at every phase, reflecting the higher health risks at lower BMI in these groups. So a BMI of 32.5, rather than 35, triggers the same eligibility test.

The three access cohorts and what each one requires

NHS England is rolling Mounjaro out in stages rather than opening access all at once. The weight-loss injection rollout is structured around three cohorts, each with its own BMI and conditions threshold.

The first cohort opened in June 2025: adults with a BMI of 40 or above and four or more of the five qualifying conditions. This is the strictest threshold and reflects the priority placed on the highest clinical need.

Cohort two activated on 23 June 2026: BMI 35 to 39.9 with four or more qualifying conditions. This broadens access significantly, though the requirement to hold four conditions simultaneously remains a high bar for many people.

Cohort three is expected around March 2027: BMI 40 or above with three or more conditions. From that point, someone with hypertension, sleep apnoea, and type 2 diabetes, for example, would meet the conditions threshold at a BMI of 40. Lower BMI thresholds for the ethnic backgrounds described above apply throughout each cohort in the same way.

NHS England's weight management guidance notes that patients in all cohorts must also participate in wrap-around support (structured diet, activity, and behavioural programmes) rather than receiving tirzepatide alone. That requirement does not go away as the phases progress.

Why meeting the criteria still does not mean automatic access

NICE's recommendation is not a direct entitlement. GP practices took on the ability to prescribe under the 2026/27 QOF contract from April 2026, but participation is voluntary. Some practices have signed up; others have not yet. Integrated Care Boards are responsible for commissioning locally, which means availability genuinely varies by area, a patient in one region may find a willing GP practice nearby, while someone elsewhere is referred to a specialist weight management service with a much longer waiting list.

If you meet the NHS conditions in principle but find access delayed or unavailable through your practice, what your options actually are is worth reading before assuming the NHS route is closed entirely. Private prescription through a regulated online pharmacy is the legal alternative, with no waiting list and no GP referral required, subject to a clinical prescriber assessing your individual circumstances. For context on what private treatment involves financially, a breakdown of what affects the cost may be useful.

Private eligibility works from the licensed criteria, not the NHS list

Mounjaro's UK marketing authorisation covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. That is a much broader population than the NHS cohorts currently reach. Private prescribers assess the full clinical picture, a BMI of 28 with hypertension could be eligible; a BMI of 42 without the right combination of NHS-listed conditions almost certainly would be too, privately.

At our pharmacy, a GPhC-registered prescriber reviews every consultation personally on the day it arrives, and if you need treatment confirmed quickly, you can request a same day Mounjaro prescription through that process. If Mounjaro is not clinically suitable, the prescriber will say so. The side-effect profile is part of that assessment, not just the BMI figure. If you want to check your eligibility without waiting, starting a free consultation is the straightforward way to find out where you stand.